PLK1 and neoplasm: In vivo studies showed that targeted delivery of Cas9/minicircle sgPLK1‐2 using LHNPs successfully edited the PLK‐1 gene in U87 subcutaneous xenograft tumor and intracranial tumor after IV injection and inhibited tumor growth.